Glax­o­SmithK­line sets its sights on a quick leap in­to the big PD-1/L1 game — will any­one no­tice?

Some­what lost in the news last fall that Glax­o­SmithK­line was buy­ing Tesaro and leap­ing in­to the com­mer­cial end of the chal­leng­ing PARP mar­ket was a PD-1 check­point in­hibitor called TSR-042 that was be­ing point­ed to a quick fil­ing for en­dome­tri­al can­cer. On Tues­day, the GSK sub­sidiary spot­light­ed a promis­ing set of Phase I/II da­ta from their GAR­NET study, and the fil­ing is on track for lat­er this year as the phar­ma gi­ant looks to make its own en­try in­to an in­creas­ing­ly crowd­ed field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER